The Inflammatory Bowel Disease Net, an official working group of the Swiss Society of Gastroenterology, has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease (IBD).
The Inflammatory Bowel Disease Net, an official working group of the Swiss Society of Gastroenterology, has issued a new position statement on the use of biosimilars in treating inflammatory bowel disease (IBD).
The position statement explains that the Swiss regulatory body, Swissmedic, requires that biosimilars be “sufficiently similar” in their structure, activity, efficacy, safety, and immunogenicity, much like the FDA’s requirement that there be no clinically meaningful differences between biosimilars and their references.
The statement goes on to say that biosimilars and biologics should be prescribed by brand name, not by international nonproprietary name (INN), because biosimilars and their reference products share INNs. Using brand names will help with postmarketing studies and monitoring programs, says the group, and global harmonization on nomenclature is desirable.
With respect to interchangeability of biosimilars with their reference products, the statement indicates that the infliximab biosimilars Inflectra and Remsima, which are the same product (CT-P13) marketed under different names, can be interchanged. The group cautions that interchanging the reference infliximab, Remicade, with biosimilars will require close monitoring for efficacy and safety.
The group strongly discourages pharmacy-level substitution, in keeping with Swissmedic’s advice that the decision to interchange products be left with prescribing physicians. “There is general concern that automatic substitution might lead to dispensing mistakes that might potentially harm patients, especially when interchangeability has not directly been demonstrated in many specific clinical settings of a given disease,” say the position statement’s authors, who add that concerns exist about pharmacovigilance, as pharmacists in Switzerland are not required to track batches of products, while prescribers must track such data.
Despite its cautions about interchangeability and substitution, the position does note that the available data on nonmedical switches from Remicade to CT-P13 do not suggest that there are adverse impacts related to switching. It also notes that immunogenicity and the frequency of adverse events have not been shown to differ between patients treated with reference or biosimilar infliximab.
However, the position also points out that, in Switzerland, unlike many other countries, healthcare providers “are currently the only beneficiaries of switching a patient from a reference product to a less-expensive biosimilar,” and patients do not see any financial benefit from undertaking a nonmedical switch. As such, nonmedical switches should be avoided, says the group.
Reference
Burri E, Juillerat P, Maillard MH, et al. Position statement on the use of biosimilars in inflammatory bowel disease. Swiss Med Wkly. 2019;149:w20148. doi: 10.4414/smw.2019.20148.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.